Inhibrx Biosciences' (INBX) Ozekibart, INBRX-106 are Lined-up For 2026 - Citizens
Tweet Send to a Friend
Citizens analyst Reni Benjamin reiterated a Market Perform rating on Inhibrx Biosciences (NASDAQ: INBX).The analyst commented, "We maintain our Market ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


